Stoke Therapeutics, Inc.
STOK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -23.1% | -91.3% | 601.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 90.7% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -363.4% | -194.4% | 70.5% | -58% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -360.7% | -170% | 71.2% | -46.4% |
| EPS Diluted | -0.65 | -0.4 | 1.9 | -0.18 |
| % Growth | -62.5% | -121.1% | 1,155.6% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |